The Skolkovo Foundation’s resident Pharma Bio has signed a long term partnership agreement with Berlin Chemie/A. Menarini , one of the leaders of the Russian and European pharmaceutical markets.
According to the agreement, which was signed at the end of December, 2012 in Skolkovo’s technopark, Pharma Bio will grant exclusive sales and marketing rights to its partner for one of the best in its product portfolio medicines. It will also render priority rights for commercialization of its future R&Ds.
As Yuri Deiguin, Pharma Bio’s executive director said, his company was one of the first residents of the Skolkovo Biomed cluster. One of their medicines, Timodepressin, which addresses the immune system diseases, including rheumatoid arthritis, psoriasis and dermatitis was noticed by Berlin Chemie/A/Menarini. One of the key advantages of the new medicine, Deiguin said, lies in its ability of softer correction of the human immune system, therefore it has less negative secondary impacts and wider implication. As Deiguin also said, cooperation with Berlin-Chemie/A. Menarini will be focused on expansion of the medicine on the Russian and the CIS markets.
Vladislav Deiguin, inventor of Timodepressin
And as the general director of Skolkovo’s technopark Sergei Kurilov noticed, the active participation of Pharma Bio in Skolkovo Foundation programs has played a substantial positive role. “One of the key advantages, which our startups are granted, is visibility, meaning an opportunity to be noticed, met potential partners, eye-to-eye, when a different type of “magic” occurs. I think this agreement is one of the most important events in the life of both technopark and Skolkvovo Foundation itself,” Sergei Kurilov said.
V. Deiguin demonstrates new medicine to the Russian premier Dmitry Medvedev at the Innovations Forum-2012
Yuri Grigoriev, the Berlin-Chemie general director, said to Sk.ru correspondent that one of the main selection criteria was the level of trust they have towards the company. This trust was based on an analysis of its results and positive feedbacks from the market. He stressed that Berlin-Chemie will soon conduct a range of clinical studies and marketing efforts in targeted regions. “The medicine looks very perspective, including its geographical distribution, we express our readiness to work together to achieve synergy with Pharma Bio, actively using our experience and contacts in the industry”, he said.
Pharma Bio is Skolkovo’s resident since 2010. The company is engaged in R&D and commercialization of new pharmaceutical products of peptide nature. The company’s product portfolio includes five original innovation medicines to cure a wide spectrum of socially important illnesses. One of the founders of Pharma Bio is the Institute of Bioorganic Chemistry, named after academicians Shemyakin and Ovchinnikov, where the company conducts its R&D.
Berlin-Chemi/A. Menarini forms part of the international pharmaceutical group Menarini, one of the leaders of the European market, which successfully operates on the Russian market for the last several decades. Currently the company builds a pharmaceutical factory in Kaluga region.
photo-album of the event